Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Digital diagnosis
February 2019
SHARING OPTIONS:

TORONTO—Winterlight Labs Inc., a company based at JLABS @ Toronto, and Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, kicked off the new year with a collaboration. Under the agreement, the companies will work together on the development of a sensitive digital biomarker that can determine which patients have mild cognitive impairment, an early stage of Alzheimer’s disease. Winterlight has an existing digital AD biomarker that is 91 percent accurate in distinguishing Alzheimer’s patients from healthy elder individuals using two minutes of speech.
 
“Early intervention is critical to slowing or halting disease progression in patients with AD,” said Liam Kaufman, CEO of Winterlight Labs.  “We’re excited to work with Janssen to help advance a novel digital biomarker that will enable early intervention and potentially help to extend the quality of life for individuals afflicted with AD.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.